DOCSLIB.ORG

Life Sciences Sector Deal 2 Industrial Strategy Life Sciences Sector Deal 2 Foreword

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Life Sciences Sector Deal 2 Industrial Strategy Life Sciences Sector Deal 2 Foreword Industrial Strategy Life Sciences Sector Deal 2 Industrial Strategy Life Sciences Sector Deal 2 Foreword Last year the Life Sciences develops to encourage and spread Sector Deal set out the first these new technologies. Advanced phase of implementing the Life therapies are making precision Sciences Industrial Strategy medicines, targeted to the individual patient, a reality here in the UK. through joint commitments between the government This second Life Sciences Sector Rt Hon Greg Clark MP and the sector to invest in the Deal deepens our partnership with industry, universities and charities and United Kingdom’s life sciences Secretary of State for Business, demonstrates how the NHS is pivotal as Energy and Industrial Strategy landscape. a delivery partner. It contains significant The agreements made in the first action to address the Industrial Strategy deal capitalised on the enormous Grand Challenges and our mission to opportunities for growth that the life transform the prevention, diagnosis sciences sector presents for the UK. and treatment of chronic diseases by We are seeing a continual flow of new 2030: it will support the creation of a investments across the health tech cohort of healthy participants that will and pharmaceutical sectors since the enable research into the hidden signs deal was published, with this year’s of disease and ways of diagnosing Rt Hon Matt Hancock MP second deal seeing more life sciences diseases early when interventions Secretary of State for companies investing in the UK and and treatments can be the most Health and Social Care creating high-quality, well-paid jobs. effective. The cohort will involve the public, the research community and Life sciences is a sector that operates industry with the results benefiting at the cutting-edge of technological the whole health service – an example developments. Government of the collective endeavours driving investments in these emerging our modern Industrial Strategy. areas are being matched by greater contributions from the sector, and We are taking action in the work this is building on existing strengths underway from the first Sector Deal, Professor Sir John Bell spanning research and healthcare to and the new commitments set out in GBE, FRS create and grow new industries in the this deal, to achieve the vision of the Regius Professor of Medicine, UK. It is right that NHS patients stand UK as a top-tier hub for life sciences The University of Oxford to benefit from these home-grown globally. The benefits will be felt by innovations. Data-driven technologies UK citizens through economic growth, have the potential to transform the good jobs and a strong and sustainable way the health system works and health service for future generations. support faster and cheaper clinical research. We must ensure the system 2 3 Industrial Strategy Life Sciences Sector Deal 2 Executive summary of NHS data, while maintaining Sector Deal, these programmes are public trust in how data is used building an ecosystem that will help The life sciences industry is one of the most important pillars of and maximising the benefits of life sciences to thrive in the UK: innovation for NHS patients. Our ```A major new commitment, the UK economy, contributing over £70bn a year and 240,000 five new centres of excellence in jobs across the country1. In 2017, a wide coalition of industry and backed by up to £79m of digital pathology and radiology funding, to develop a first-of- charity partners, led by Professor Sir John Bell, published a bold will provide more precise diagnosis, 2 its-kind, world-leading cohort Life Sciences Industrial Strategy that set a clear direction for the applying AI tools to digital images to of healthy participants that will sector’s future growth. detect abnormalities more quickly attract significant global investment and accurately than humans. They The strategy was underpinned by the globally-successful entities; and the need from industry and charities. The will also help to reduce costs. very significant competitive advantages to drive up research and development project will enable research into the UK already possesses – an funding to remain globally competitive. ```We are delivering on our aim to make the hidden signs of disease and the UK a global hub for advanced the development of tools to detect outstanding research base in world- The government’s response to this therapies and building an impressive and diagnose diseases earlier. This class universities; significant capabilities call from industry came with the first end-to-end national infrastructure will lead to a type of ‘predictive in clinical and translational medicine in Life Sciences Sector Deal3, a key part through a £146m commitment prevention’ which is crucial to ensure the NHS; longitudinal datasets within a of the modern Industrial Strategy. to medicines manufacturing. This the NHS has a sustainable future. national healthcare system; the largest The deal included close to £500m includes: doubling capacity at the biotech cluster outside the United of government support for major `` A world-first commitment to Cell and Gene Therapy Catapult States; a highly-productive and skilled new research programmes and over sequence one million whole Manufacturing Centre; three new workforce; and strong capabilities £1bn of new industry investment. genomes in the UK within the advanced therapies treatment centres; in emerging fields, such as digital It brought together partners from next five years including 500,000 and two new innovation centres for health and artificial intelligence (AI). across the pharmaceutical and health through the NHS in addition to the vaccines and medicines manufacturing. Taking these strengths as the basis for tech sectors, charities, government 500,000 in the UK Biobank project. future growth, the strategy set out how agencies and the NHS to deliver its ```The government, industry, the NHS Our broader aspiration is to reach to maintain and build on them under vision at pace. Strong progress is and its partners are delivering on five million genomic analyses in the fierce international competition, and to being made on implementation: their clear commitment to work same timeframe, truly making the UK together to improve the innovation the home of genomic healthcare. capitalise on emerging opportunities. ```An investment of £85m in our and access environment in the It set a roadmap for the UK to create already world-leading genomics `` An additional £50m investment in UK, with strong progress made on whole new industries over the next assets at UK Biobank has attracted our digital pathology programme as implementing the Accelerated two decades in the fields of early significant support for what will be a first step towards making this a truly Access Review4, supported by disease detection and genomics; the largest whole genome sequencing national asset to support early and £86m in government funding. digital technologies and data analytics; project ever undertaken. A £30m improved diagnosis across the UK and and in advanced therapeutics. vanguard study, the first phase of One year on, we are now going deliver more efficient NHS services. further still through this second Life The strategy also set out the areas work, is already underway, sequencing ``` £37.5m funding and a plan for where key developments could fix the first 50,000 participants. Sciences Sector Deal with significant a network of regional Digital additional measures and innovative issues which have slowed down growth; ``` In digital technologies and data Innovation Hubs, providing expert programmes to secure a global lead such as NHS uptake of innovative analytics, we are laying down the clinical research data services, data in the areas of greatest opportunity technologies; the difficulty in scaling building blocks to realise the full analysis and sharing capabilities. for the UK. Together with the first UK biotech companies to create large, potential of the scale and diversity This is part of a wider programme 4 5 Industrial Strategy Life Sciences Sector Deal 2 delivering on the government’s tech ``` Measures to support the supply vision to reform the architecture of capital for innovative firms, of technology in the NHS and helping them to grow, through the make it work better for patients, government’s Patient Capital Review5. Life Sciences clinicians and researchers. Industry partners have responded ``` A wide-ranging new policy package to this significant commitment Sector Deal to support uptake and adoption of with further investment: innovation in the NHS and ensure ```UCB, a global pharmaceutical the UK continues to be a world company, is investing in one Key commitments leader in health tech. Through of their two major global R&D its long-term plan and the recent hubs in the UK. This will involve a branded medicines pricing deal, the purpose-built, state-of-the-art facility NHS will set out how it will be a crucial to enable cutting-edge R&D, early national partner, acting as both a manufacturing and commercial real-world testbed and a beneficiary operations, with planned investment of many of the innovations flowing of £150-200m in the facility and from the life sciences industry. around £1bn total investment Wider policy measures are reinforcing over five years. The transition this approach, including: to the new facility will support ```A suite of measures to make our around 650 high-value jobs across clinical research environment R&D, enabling further collaborations faster, more
Load more

Recommended publications
  • London: an Innovation Hub for Health & Life Sciences Through
    LONDON: AN INNOVATION HUB FOR HEALTH & LIFE SCIENCES THROUGH THE APPLICATION OF DATA AND AI SUPPORTED BY Next page Access the market: 19 from NHS to Biopharma CONTENTS Foreword 3 The NHS adoption of AI technologies 20 This is an interactive guide, London’s key strengths 4 l Spotlight on UCLPartners 21 so click on the title to jump to any section. An Innovative Biopharma Cluster 22 An ecosystem built for growth 5 l Case study - MultiplAI 23 Access to funding 6 Government support 7 An accessible, diverse 24 l Case study - Kheiron Medical 9 and data-rich environment Diverse population and data 24 London’s life sciences clusters 10 Partner with the Health Data 25 The Knowledge Quarter 11 Research Hubs Whitechapel: Barts Life Sciences Hub 12 l Spotlight on DATA-CAN HDR 26 White City Innovation District 13 Southbank to Sutton 14 London’s resilient COVID-19 response 27 l Case study - InstaDeep 28 Talent and educational excellence 15 Existing talent 16 How can we help 29 The next generation 17 How London & Partners can support 29 l Case study - PEP Health 18 How MedCity can support 29 2 Contents page FOREWORD COVID-19 has accelerated data-driven innovation across often siloed organisations. Similarly, policy is being the globe, with artificial intelligence and data science at developed to overcome legacy systems and regulations, the forefront of addressing human disease and health. which will underpin and speed up innovations. The coronavirus pandemic has led to increased acceptance of new technologies with strong buy-in from all corners Not only can bioinformatics and use of healthcare Allen Simpson Neelam Patel data lead to better health systems and outcomes, this of the life sciences and healthcare sector determined to CEO also has the potential to create many new jobs Acting CEO keep this momentum going.
    [Show full text]
  • Helen Lawton Smith & Sharmistha Bagchi-Sen
    The London-Oxford-Cambridge (Southeast) Golden Research Triangle: hype or reality? -- A bio-innovation complex to overtake US Helen Lawton Smith & Sharmistha Bagchi-Sen Presentation at CIMR workshop, June 29 2016 Focus of the presentation (i) the incentives for leading UK entrepreneurial universities to work together in this project and the inherent facilitators and inhibitors, – organizational factors facilitating or hindering endeavours where inter-organisational collaboration is required (ii) the value-added from being where they are and the extent of accrued local cluster assets that they bring to the venture – the existing landscape of translational research and the extent to which local factors facilitate the process (iii) how the hierarchies of policies (local, national) shape the environment for collective action, – how can such actions be evaluated? The talk structure 1. UK context 2. Barriers and potential of "golden triangle” 3. MedCity in theory and practice 4. Reflections on prospects Research questions • What are the factors which will influence whether or not the MedCity initiative will be sustainable? • What is different now compared to earlier efforts to build a biomedical science cluster in London? – E.g. 2006 – plan for Global Medical Excellence Cluster Context • UK Industrial Strategy for Life Science (2011) proposes that the UK is made into “a world-leading place for life sciences investment and a global hub for life sciences” (page 4). UK Context • Pharmaceuticals, medical biotechnology and medical technology sectors together comprise around 4,500 firms, employing 165,000 staff, with an R&D spend of nearly £5billion and an annual turnover of over £50 billion. • Of the top 50 global pharmaceutical companies, 37 have sites in the UK • Largest biopharmaceutical pipeline in the EU – 20% • Life sciences map of companies – 3 largest centres are in Golden triangle Important initiatives in life sciences research and translation • Francis Crick Institute (opening 2016) – The Crick aspires to be one of the world's leading medical research institutes.
    [Show full text]
  • Life Sciences in London and the South East 02–03 Medcity at a Glance: Life Sciences in London and the South East Welcome
    At a glance Life sciences in London and the south east 02–03 MedCity At a glance: Life sciences in London and the south east Welcome The ‘golden triangle’ is the The golden triangle is being boosted world-leading life sciences cluster further by a wave of significant new of London, Oxford, Cambridge and investment, including: England’s greater south east. The Francis Crick Institute – At a glance: Life sciences in London bringing together 1,500 scientists and the south east has been created under one roof to help you navigate this exciting Imperial West – co-locating ecosystem. It provides a snapshot of researchers and businesses this evolving community, its current on 25 acres strengths and the plans for future UCL East – a cross-discipline investment and growth. enterprise and innovation centre focused on health and biological This cluster is a rich network of technologies on the site of renowned research centres, healthcare Queen Elizabeth Olympic Park providers and medical charities, The Institute of Cancer Research innovative SMEs and large industry – creating the world’s second largest players, all based within a compact and cancer research campus in south London well-connected geographical region. AstraZeneca’s Global R&D Centre – bringing together 2,000 employees in Cambridge This region is a hotbed of innovation, home to: To maximise this wave of new investment four of the world’s top MedCity was launched in April 2014. 10 universities This unique enterprise is your portal to five out of seven of the UK’s the diverse expertise, innovation and academic health science centres infrastructure of the region.
    [Show full text]
  • Employment Land Needs Assessment
    Employment Land Needs Assessment Oxford City Council Final Report October 2018 Prepared by GL Hearn 280 High Holborn London WC1V 7EE T +44 (0)20 7851 4900 glhearn.com Employment Land Needs Assessment October 2018 Oxford City Council, Final Report Contents Section Page 1 EXECUTIVE SUMMARY 4 2 INTRODUCTION 7 3 REVIEW OF RECENT EVIDENCE 8 4 PROPERTY DYNAMICS 13 5 EMPLOYMENT FORECASTING 22 6 EMPLOYMENT LAND NEEDS 31 GL Hearn Page 2 of 38 Employment Land Needs Assessment October 2018 Oxford City Council, Final Report Quality Standards Control The signatories below verify that this document has been prepared in accordance with our quality control requirements. These procedures do not affect the content and views expressed by the originator. This document must only be treated as a draft unless it is has been signed by the Originators and approved by a Business or Associate Director. DATE ORIGINATORS APPROVED October 2018 Nena Pavlidou Paul McColgan Senior Planner Associate Director Limitations This document has been prepared for the stated objective and should not be used for any other purpose without the prior written authority of GL Hearn; we accept no responsibility or liability for the consequences of this document being used for a purpose other than for which it was commissioned. GL Hearn Page 3 of 38 Employment Land Needs Assessment October 2018 Oxford City Council, Final Report 1 EXECUTIVE SUMMARY i. There are an estimated 135,400 jobs in Oxford in 2016. Oxfordshire is home to some of the UK’s principal locations for high quality knowledge-based economic growth. Firstly, the University of Oxford has the country’s largest volume of world-leading research companies.
    [Show full text]
  • London's Innovation Districts
    SPACES TO THINK: INNOVATION DISTRICTS AND THE CHANGING GEOGRAPHY OF LONDON’SKat Hanna KNOWLEDGE ECONOMY SPACES TO THINK: INNOVATION DISTRICTS AND THE CHANGING GEOGRAPHY OF LONDON’S KNOWLEDGE ECONOMY Kat Hanna Published by Centre for London, April 2016 Open Access. Some rights reserved. As the publisher of this work, Centre for London wants to encourage the circulation of our work as widely as possible while retaining the copyright. We therefore have an open access policy which enables anyone to access our content online without charge. Anyone can download, save, perform or distribute this work in any format, including translation, without written permission. This is subject to the terms of the Centre for London licence. Its main conditions are: · Centre for London and the author(s) are credited · This summary and the address www.centreforlondon.org are displayed · The text is not altered and is used in full · The work is not resold · A copy of the work or link to its use online is sent to Centre for London. You are welcome to ask for permission to use this work for purposes other than those covered by the licence. Centre for London gratefully acknowledges the work of Creative Commons in inspiring our approach to copyright. To find out more go to www.creativecommons.org Published by: Centre for London 2016 © Centre for London. Some rights reserved. 1 Plough Place London EC4A 1DE T: 020 3757 5555 [email protected] www.centreforlondon.org Company Number: 8414909 Charity Number: 1151435 Typeset by Soapbox, www.soapbox.co.uk Centre for London is a politically independent, not‑for‑profit think tank focused on the big challenges facing London.
    [Show full text]
  • 2018 Programme
    Shifting perceptions? The challenges and opportunities of the Fourth Industrial Revolution 28 November 2018 2 3 Contents Agenda 11.00 Registration and networking Today, the Huxley Summit will bring together leaders from 12.00 Chapter 1: The changing tide of public perception Since the 1950s, plastic has been seen as a problem-solving wonder. However, business, policy-making and science to discuss how we can the recent public and media reaction to single-use plastics following Blue ensure products of innovation are fit for purpose as societal, Planet II has raised many questions for businesses, policy-makers and scientists. How do businesses create confidence and trust from consumers in environmental and cultural expectations change and shift. How products that could impact society and the environment? How do institutions does society overcome the challenges of the ‘Fourth Industrial manage this risk and learn from past decisions? Revolution’ and a potential breakdown of trust in technology Speakers include: Liz Bonnin, Zoe Laughlin, Emma Howard Boyd, Rory Sutherland, Baroness Lucy Neville-Rolfe from the public? There will be provocations and debates, plus time for networking and focussed discussions about how we 13.20 Roundtable discussions and lunch navigate the future. 14.50 Chapter 2: Preparing for the future Part A: Short-term challenges vs. long-term risks How can leaders in boardrooms and government consider changing perceptions in different technical and cultural spheres to create responsible innovations? This panel will discuss how boards can balance long-term risks Page 3 Agenda and impacts with short-term challenges. Page 4 Welcome Speakers include: Linda Yueh, Marisa Drew, David Bucknall Part B: Artificial perceptions of AI? Page 6 Public opinion is Artificial intelligence is heralded by technologists, business leaders, and policy- powerful and makers as a wonder technology with the potential to solve global problems unpredictable such as health, climate change, and inequality.
    [Show full text]
  • Mapping the Landscape of UK Health Data Research & Innovation
    Mapping the Landscape of UK Health Data Research & Innovation A snapshot of activity in 2017 Dr Ekaterini Blaveri October 2017 CONTENTS Foreword 5 1. Background to this review 7 1.1. Aims 8 1.2. Scope and sections 8 1.3. Approach 9 1.4. Challenges 10 1.5. Acknowledgements 10 2. Overview of major informatics investments by Funder 11 2.1. MRC 12 2.1.1. The Farr Institute of Health Informatics Research 12 2.1.2. MRC Medical Bioinformatics initiative 16 2.1.3. MRC Capital Investment in Genomics England Data Infrastructure 19 2.2.1. The NIHR Biomedical Research Centres 21 2.2.2. The NIHR Health Informatics Collaborative programme 22 2.2.3. The NIHR Collaboration for Leadership in Applied Health Research and Care 25 2.3. Department of Health and Social Care 26 2.3.1. Academic Health Science Centres 26 2.3.2. Genomics England | 100,000 Genomes Project 27 2.4. NHS 28 2.4.1. Academic Health Science Networks 28 2.4.2. NHS Genomic Medicine Centres 30 2.4.3. NHS Global Digital Exemplars 31 2.5. ESRC’s investments in Big Data 32 2.5.1. Administrative Data Research Network 32 2.6. EPSRC’s health data research investments 33 3. Key informatics investments by Research Organisation 35 England – East Anglia and Midlands 38 University of Cambridge 41 EMBL-European Bioinformatics Institute 48 Wellcome Sanger Institute 52 University of Birmingham 56 University of Leicester 62 University of Warwick 68 England – London 74 Imperial College London 76 King’s College London 85 London School of Hygiene and Tropical Medicine 94 Queen Mary University of London 98 University
    [Show full text]
  • Accessing Research and Clinical Expertise Accessing Research And
    Accessing researchResearch and Clinical Expertise in LondonCambridge, and London,the South Oxford East and the Greater South East 1 About the NIHR The National Institute for Health Research (NIHR) is funded by the Department of Health to improve the health and wealth of the nation through research. Since its establishment in April 2006, the NIHR has transformed research in the NHS. It has increased the volume of applied health research for the benefit of patients and the public, driven faster translation of basic science discoveries into tangible nihr.ac.uk benefits for patients and the economy, and developed and supported the people @officialNIHR who conduct and contribute to applied health research. The NIHR plays a key role in the Government’s strategy for economic growth, attracting investment by the life-sciences industries through its world-class infrastructure for health research. Together, the NIHR people, programmes, centres of excellence and systems represent the most integrated health research system in the world. About NOCRI The NIHR Office for Clinical Research Infrastructure (NOCRI) helps public, charity and industry research funders work in partnership with NIHR infrastructure and to maximise the impact of the Department of Health’s £0.5b/year investment in clinical research infrastructure. Equally, it ensures that NIHR-supported centres, units, facilities and networks can work together to help drive the flow of innovative research for patient benefit. nihr.ac.uk/nocri NOCRI supports research partners by: @NIHR_NOCRI • Research signposting - help with navigating the clinical research environment and finding expert researchers and world class facilities and technologies • Research collaboration management - support for the development of collaborative research partnerships About MedCity MedCity exists to promote and grow life sciences investment, entrepreneurship, collaboration and industry in Cambridge, London, Oxford and the greater south east.
    [Show full text]
  • Downloads/Collabor.Pdf
    Geographical clusters (March 2015) Summary of a FORUM workshop held on 3 March 2015 hosted jointly by the Academy of Medical Sciences and the Wellcome Trust. The Academy of Medical Sciences The Academy of Medical Sciences is the independent body in the UK representing the diversity of medical science. Our mission is to promote medical science and its translation into benefits for society. The Academy’s elected Fellows are the United Kingdom’s leading medical scientists from hospitals, academia, industry and the public service. We work with them to promote excellence, influence policy to improve health and wealth, nurture the next generation of medical researchers, link academia, industry and the NHS, seize international opportunities and encourage dialogue about the medical sciences. The Academy of Medical Sciences’ FORUM The Academy’s FORUM was established in 2003 to recognise the role of industry in medical research, and to catalyse connections across industry and academia. Since then, a range of FORUM activities and events have brought together researchers, research funders and research users from across academia, industry, government, and the charity, healthcare and regulatory sectors. The FORUM is a major component of the Academy's work to deliver the strategic objective of 'linking academia, industry and the NHS' and its success relies on supporter organisations who make an annual donation. We are grateful for the support provided by the members and are keen to encourage more organisations to take part. If you would like information on becoming a member please contact [email protected]. The Wellcome Trust The Wellcome Trust is a global charitable foundation dedicated to improving health.
    [Show full text]
  • Health Innovation: Breathing Life Into the Northern Powerhouse ABOUT the AUTHOR Luke Raikes Is a Research Fellow at IPPR
    REPORT HEALTH INNOVATION BREATHING LIFE INTO THE NORTHERN POWERHOUSE Luke Raikes November 2016 © IPPR North 2016 Institute for Public Policy Research ABOUT IPPR NORTH SUPPORTED BY IPPR North is IPPR’s dedicated thinktank for the North of England. With its head office in Manchester and representatives in Newcastle, IPPR North’s research, together with our stimulating and varied events programme, seeks to produce innovative policy ideas for fair, democratic and sustainable communities across the North of England. IPPR’s purpose is to conduct and promote research into, and the education of the public in, the economic, social and political sciences, science and technology, the voluntary sector and social enterprise, Established in 2011, NHSA Ltd represents the eight public services, and industry and commerce. research-intensive universities (also known as the N8), eight research-intensive NHS teaching trusts and four IPPR North academic health science networks (AHSNs), and works 13th Floor, City Tower to promote and partner the North with international Piccadilly Plaza, Manchester M1 4BT clinical research in the public and private sector. T: +44 (0)161 694 9680 E: [email protected] www.ippr.org/north Registered charity no: 800065 (England and Wales), SC046557 (Scotland). This paper was first published in November 2016. © 2016 The contents and opinions expressed in this paper are those of the author only. IDEAS to CHANGE LIVES CONTENTS Summary ................................................................................................ 3 1. Introduction and context .................................................................... 6 1.1 The strengths of the northern health science sector ...................... 6 1.2 The Northern Independent Economic Review ................................ 7 1.3 The northern powerhouse and place-based industrial strategy .....
    [Show full text]
  • Relational Regions 'In the Making': Institutionalising
    RELATIONAL REGIONS ‘IN THE MAKING’: INSTITUTIONALISING NEW REGIONAL GEOGRAPHIES OF HIGHER EDUCATION John Harrison* / Darren P Smith / Chloe Kinton Department of Geography School of Social, Political and Geographical Sciences Loughborough University Loughborough United Kingdom LE11 3TU +44(0)1509 228198 [email protected] / [email protected] / [email protected] *Author for correspondence Final author version – February 2017 Accepted for publication in Regional Studies. Page | 1 Abstract This paper advances current debates on relational regions and higher education through a unique focus on the rise of transregional university alliances. We examine the formation of university research and training consortia to make a series of wider arguments about the new spatialities of higher education praxis, the construction of new regional identities, and processes of institutionalising relational regions. Our research shows new partnership working between universities to be conducive to the weakening of fixed regional territories. It then illustrates how and why some relational imaginaries are beginning to crystallise into harder institutional forms, before revealing significant political- economic and societal implications arising from new institutional geographies of higher education. Furthermore, our research reveals the concerted theoretical and empirical attention required to develop vocabulary and frameworks better able to comprehend emergent regional worlds. For our part, we distinguish between territorial, archipelagic, de facto
    [Show full text]
  • Steeped in Science
    NATURE INDEX | SCIENCE CITIES PHIL SAYER A laboratory at King's College London. The university hospital is part of MedCity, a collaborative organization that aims to spur the translation of science. STEEPED IN SCIENCE For centuries a hub of ideas and trade, London is embracing ambitious developments to boost research and local connections, despite the uncertainty caused by Brexit. BY ANNA PETHERICK of peer-reviewed publications in the journals to the rest of the UK. Institutions in London tracked by the Nature Index each year. The city contribute to life sciences papers in the Nature ondon has historically been a science centre is less than an hour from both Cambridge Index as frequently as they contribute to chem- megacity. In 1665 it saw the launch of the and Oxford, forming the central node of the istry and physical sciences papers combined. world’s first science journal, Philosophi- UK’s scientific golden triangle. This is thanks, in part, to the UK’s three main Lcal Transactions. A walk through the West End Though scientists are concerned about the university hospital systems — King’s College takes you through the same streets that led to outcome of the Brexit negotiations, particularly London, Imperial College London and UCL — the Broad Street pump on John Snow’s map on immigration, regulation and the UK’s access located in the city. The latter two rank among of cholera, his original evidence for the germ to European Union research funds, London’s the global top 10 in the QS World University theory of disease. business community, mayor and people are Rankings and in the top 40 in the Nature Index.
    [Show full text]